In the US, the Food and Drug Administration has designated psilocybin a ‘breakthrough treatment’ for depression. We are working to reschedule psilocybin in the UK to support scientific research into psilocybin-assisted therapy.
We are in the midst of a depression epidemic
Millions of people in the UK are suffering from poor mental health, including depression that is resistant to current treatments.
We are working with politicians and mental health professionals to support UK research by rescheduling psilocybin to Schedule 2. This would help lift restrictions on research while continuing to appropriately mitigate risk.
Backed by leading drug policy organisations…
…and a cross-party coalition of MPs
Learn more about Imperial College London’s new
Centre for Psychedelic Research
The UK has the chance to become a world leader in a breakthrough treatment for depression
The UK government now has an opportunity to expedite groundbreaking new research that could revolutionise the treatment of depression by rescheduling psilocybin.